Molecular Weight(MW): 351.4
Meloxicam is a selective COX inhibitor, used to relieve pain and fever effects.
1 Customer Review
Meloxicam (0.25 μg/ml) decreases the migration of CF41.Mg cells. Incubation with 0.25 μg/ml meloxicam for 24 and 48 h inhibited the migration of cells compared with the DMSO‑treated control cells in a wound healing assay. A total of 6 repeats were performed and results are presented as the mean ± standard deviation. Representative images of the wound healing assay and quantification if the results are presented. Scale bar, 90 μm. *P<0.05 vs. the control group.
Oncology letters, 2017, 2198-2206. Meloxicam purchased from Selleck.
Purity & Quality Control
Choose Selective COX Inhibitors
|Description||Meloxicam is a selective COX inhibitor, used to relieve pain and fever effects.|
Meloxicam significantly reduces HCA-7 and Moser-S colony size. Meloxicam significantly inhibits HCA-7 colony and tumor growth but has no effect on the growth of the COX-2 negative HCT-116 cells.  Meloxicam inhibits PGE(2) production, proliferation and invasiveness especially in MG-63 cells, which express relatively high levels of COX-2. Meloxicam causes apoptosis and upregulates Bax mRNA and protein in MG-63 cell culture. 
|In vivo||Meloxicam suppresses LM-8 tumor growth and lung metastasis in vivo mouse model.  Meloxicam causes a significant reduction in lameness at post injection hour (PIH) 8 and 24 and tends to reduce effusion in horse. Meloxicam significantly suppresses synovial fluid (SF) prostaglandin E2 and substance P release at PIH 8 and bradykinin at PIH 24 compared to placebo treatment in horse. Meloxicam reduces general MMP activity at PIH 8 and 24 in horse.  Meloxicam- or flunixin-treated horses has improved postoperative pain scores and clinical variables, compared with SS-treated horses. Meloxicam results in high numbers of neutrophils in ischemia-injured tissue of horse.  Meloxicam administration significantly suppresses PGE2 concentrations in blood and synovial fluid at days 7 and 21, but has no effect on concentrations of TXB2 in blood or PGE2 in gastric mucosa in dogs. |
-  Goldman AP, et al. Carcinogenesis, 1998, 19(12), 2195-2199.
-  Naruse T, et al. Carcinogenesis, 2006, 27(3), 584-592.
-  de Grauw JC, et al. Equine Vet J, 2009, 41(7), 693-699.
|In vitro||DMSO||30 mg/mL (85.37 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02448199||Not yet recruiting||Osteoarthritis||Zodiac Produtos Farmaceuticos S.A.|Eurotrials Brasil Consultores Cientificos Ltda||July 2015||Phase 3|
|NCT02403687||Enrolling by invitation||Arthritis|Tendonitis|Gout|Radiculopathy|Muscle Spasms|Synovitis|Migraine|Headache||Express Specialty Pharmacy||June 2015||--|
|NCT02405793||Withdrawn||Osteoarthritis||Iroko Pharmaceuticals, LLC||May 2015||Phase 2|
|NCT02255045||Recruiting||Dysmenorrhea||Laboratorios Andromaco S.A.||July 2014||Phase 2|Phase 3|
|NCT02060006||Unknown status||Tuberculosis||University of Stellenbosch|University of Pittsburgh||April 2014||Phase 3|
|NCT02078102||Recruiting||Multiple Myeloma|Non-Hodgkins Lymphoma||Sherif S. Farag|National Cancer Institute (NCI)|Indiana University||March 2014||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.